Abstract

Non-small cell lung cancer (NSCLC) accounts for more deaths than any other cancer. Treatments are limited, and prognoses are usually very poor. Amitripyline is a tricyclic antidepressant with multiple effects which may give a variety of benefits to lung cancer patients. Effects on pain, mood, and sleep are of clear potential benefit and are well established, whereas effects on cough and respiratory function are currently under investigation. In addition, potential antitumour effects have yet to be comprehensively tested. Beneficial effects are limited by dose dependent toxicity and adverse effects. Nevertheless, amitriptyline appears to have place in the management of lung cancer and warrants further investigation.

Keywords: Amitriptyline, lung cancer, non-small cell lung cancer, NSCLC.